Effect of Spontaneous Breathing in APRV Mode on Respiratory Physiology of ARDS Patients (SBA-APRV)
A Randomized Controlled Trial Of The Effect Of Spontaneous Breathing In APRV Mode On Respiratory Physiology In Patients With Acute Respiratory Distress Syndrome
研究概览
地位
条件
详细说明
Acute respiratory distress syndrome (ARDS) is a life-threatening critical respiratory illness characterized by heterogeneous pulmonary injury and severe ventilation-perfusion mismatch. Airway Pressure Release Ventilation (APRV) permits spontaneous breathing throughout the whole respiratory cycle, which may improve regional ventilation-perfusion matching and hemodynamic status. Nevertheless, excessive spontaneous breathing effort may trigger pendelluft phenomenon, augment regional lung strain and precipitate patient-self-inflicted lung injury (P-SILI). To date, the safe intensity range of spontaneous breathing during APRV for moderate-to-severe ARDS patients has not been well defined.
This single-center, randomized 3-period crossover self-controlled physiological trial enrolls ICU adult patients aged 18-80 years, diagnosed with moderate-to-severe ARDS (PaO₂/FiO₂ ≤ 150 mmHg) within 48-hours of invasive mechanical ventilation. After written informed consent obtained from legal surrogates, subjects will first receive a 60-minute baseline ventilation period following ARDSnet low-tidal-volume pressure-control ventilation strategy under deep sedation without spontaneous breathing. Subsequently, every participant will undergo three APRV intervention states in computer-generated random order: Condition A: APRV with low-intensity spontaneous breathing (spontaneous-contributed minute ventilation 10%-30%); Condition B: APRV with high-intensity spontaneous breathing (31%-50%); Condition C: APRV with fully suppressed spontaneous breathing via deep sedation (RASS -4 to -5). Each intervention maintains target spontaneous-breathing intensity for 30-minute stabilization before data collection. A mandatory 30-minute wash-out phase will be implemented between successive interventions to revert subjects back to baseline pressure-control ventilation and sedation status.
Primary endpoint is the comparison of ventilation-perfusion mismatch percentage (mismatch%, calculated as sum of dead-space fraction and shunt fraction) among three states measured by bedside EIT. Secondary endpoints contain multiple EIT quantitative indices, respiratory mechanics parameters (including esophageal-pressure-derived transpulmonary pressure), hemodynamic and right-ventricular function, diaphragmatic ultrasound indices, arterial blood gas variables. Adverse events related to respiratory, circulatory and operational procedures are closely monitored as safety outcomes.
Planned sample size is 14-16 enrolled participants to achieve 12 evaluable subjects completing all three intervention sequences considering dropout rate. All ventilator and sedation modifications are short-term and reversible; standard clinical therapeutic regimens will not be altered except for study-related procedures. After finishing all three intervention periods, ventilator and sedation settings will be returned to clinical team's discretion. Linear mixed-effect models will be applied for statistical analysis of crossover-design data.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Xiaojing Zou
- 电话号码:+86-27-85351606
- 邮箱:249126734@qq.com
学习地点
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
接触:
- Xiaojing Zou
- 电话号码:+86-27-85351606
- 邮箱:249126734@qq.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
1. Age ≥18 and ≤80 years old. 2. Diagnosed with moderate-to-severe ARDS according to the 2023 global ARDS definition.
3. Within 48 hours of invasive mechanical ventilation. After 1-hour low-tidal-volume pressure-controlled ventilation following ARDSnet strategy, arterial blood gas shows PaO₂/FiO₂ ≤ 150 mmHg.
4. Written informed consent is obtained from the patient or their legal surrogate decision-maker after full explanation of the study by the principal investigator or authorized study physician.
Exclusion Criteria:
1. Refractory shock defined as persistent hyperlactatemia and/or prolonged capillary refill time, fluid-resistant, requiring norepinephrine ≥ 0.5 μg/kg/min.
2. Severe chronic medical conditions severely affecting cardiopulmonary function: severe chronic obstructive pulmonary disease, interstitial lung disease, pulmonary embolism, right-heart failure, pulmonary hypertension, or severe arrhythmia.
3. Radiologically confirmed bronchopleural fistula, status post lobectomy, or other major thoracic surgery.
4. Contraindications to electrical impedance tomography (EIT): extensive chest skin injury or infection, implanted cardiac pacemaker or defibrillator, etc.
5. Contraindications for esophageal manometry placement: esophageal obstruction, perforation, severe esophageal varices, etc.
6. Diaphragmatic hernia, severe chest wall deformity, or significant pulmonary bullae.
7. Significant coagulation abnormalities (PT or APTT prolonged ≥2 times upper limit of normal, or INR>2.0) with active bleeding risk.
8. Severe intracranial hypertension (>20 mmHg), severe traumatic brain injury (GCS ≤8), or neuromuscular disorders.
9. Pregnant or breastfeeding women. 10. Patients already receiving ECMO therapy. 11. Expected survival time <24 hours judged by attending physician. 12. Body mass index (BMI) >35 kg/m². 13. Previously enrolled in this study or participating in other interventional clinical trials.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Low-level spontaneous breathing under APRV
APRV ventilation with spontaneous-contributed minute-ventilation proportion maintained at 10%-30%.
A stabilization period of 30 minutes is performed before data collection
|
APRV ventilation mode, spontaneous-contributed minute-ventilation proportion maintained at 10%-30%.
30-minute stabilization before outcome measurement.
|
|
实验性的:High-level spontaneous breathing under APRV
APRV ventilation with spontaneous-contributed minute-ventilation proportion maintained at 31%-50%.
A stabilization period of 30 minutes is performed before data collection.
|
APRV ventilation mode, spontaneous-contributed minute-ventilation proportion maintained at 31%-50%.
30-minute stabilization before outcome measurement.
|
|
实验性的:Fully suppressed spontaneous breathing under APRV
APRV ventilation with spontaneous breathing completely suppressed by deep sedation (RASS-4 to -5).
A stabilization period of 30 minutes is performed before data collection.
|
APRV ventilation mode, spontaneous breathing fully suppressed by deep sedation (RASS-4 to -5).
30-minute stabilization before outcome measurement.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Ventilation-perfusion mismatch percentage (Mismatch%)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Ventilation-perfusion mismatch percentage (Mismatch%), calculated as the sum of dead-space percentage and shunt percentage measured by electrical impedance tomography (EIT).
A composite index reflecting overall ventilation-perfusion mismatch, assessed at baseline and under three APRV experimental conditions.
Unit: %
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Match percentage(match%)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Match percentage derived from electrical impedance tomography (EIT).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Pendelluft amplitude
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Pendelluft amplitude derived from electrical impedance tomography (EIT).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Dead-space percentage
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Dead-space percentage derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Shunt percentage
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Intrapulmonary shunt percentage derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Global inhomogeneity index (GI)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period
|
Global inhomogeneity index (GI) derived from electrical impedance tomography (EIT).
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period
|
|
Center of ventilation (CoV)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Center of ventilation (CoV) derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Tidal recruitment-derecruitment
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Tidal recruitment-derecruitment (Tidal R/D) derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Ventilation distribution
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Regional ventilation distribution derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Perfusion distribution
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Regional pulmonary perfusion distribution derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Peak airway pressure (Ppeak)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Airway peak pressure (Ppeak) measured by mechanical ventilator, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Plateau pressure (Pplat)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Airway plateau pressure (Pplat) obtained from end-inspiratory hold maneuver, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Driving pressure (ΔP)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Driving pressure (ΔP) derived from mechanical ventilator measurements.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Static respiratory system compliance (Cstat)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Static respiratory system compliance (Cstat), assessed at baseline and under three APRV experimental conditions.
Unit: mL/cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
End-inspiratory esophageal pressure (PesI)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
End-inspiratory esophageal pressure (PesI) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
End-expiratory esophageal pressure (PesE)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
End-expiratory esophageal pressure (PesE) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Esophageal pressure swing (ΔPes)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Esophageal pressure swing (ΔPes) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
End-inspiratory transpulmonary pressure (PtpI)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
End-inspiratory transpulmonary pressure (PtpI) derived from airway and esophageal pressure measurements.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Transpulmonary driving pressure (ΔPtp)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Transpulmonary driving pressure (ΔPtp) derived from airway and esophageal pressure measurements.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
End-expiratory transpulmonary pressure (PtpE)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
End-expiratory transpulmonary pressure (PtpE) derived from airway and esophageal pressure, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Esophageal pressure-time product per minute (PTPes/min)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Esophageal pressure-time product per minute (PTPes/min) read directly from the ventilator interface.
Unit: cmH₂O·s/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Dynamic transpulmonary driving pressure (ΔPL,dyn)
大体时间:At the end of each 30-minute APRV experimental condition (after stabilization)
|
Dynamic transpulmonary driving pressure (ΔPL,dyn) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O.
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Inspiratory muscle pressure (Pmus)
大体时间:At the end of each 30-minute APRV experimental condition (after stabilization)
|
Inspiratory muscle pressure (Pmus) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
End-expiratory occlusion pressure (ΔPocc)
大体时间:At the end of each 30-minute APRV experimental condition (after stabilization)
|
End-expiratory occlusion pressure (ΔPocc) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Airway occlusion pressure (P0.1)
大体时间:At the end of each 30-minute APRV experimental condition (after stabilization)
|
Airway occlusion pressure (P0.1) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Muscular pressure index (PMI)
大体时间:At the end of each 30-minute APRV experimental condition (after stabilization)
|
Muscular pressure index (PMI) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Negative inspiratory force (NIF)
大体时间:At the end of each 30-minute APRV experimental condition (after stabilization)
|
Negative inspiratory force (NIF) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Heart rate
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Heart rate from continuous bedside monitoring, assessed at baseline and under three APRV experimental conditions.
Unit: beats per minute.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Mean arterial pressure (MAP)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Mean arterial pressure (MAP) measured via invasive arterial catheter, assessed at baseline and under three APRV experimental conditions.
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Vasopressor dosage (μg/kg/min)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Dosage of vasoactive medications, assessed at baseline and under three APRV experimental conditions.
Unit: μg/kg/min
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Central venous pressure (CVP)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Central venous pressure (CVP), assessed at baseline and under three APRV experimental conditions.
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Right-ventricular fractional area change
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Right-ventricular fractional area change measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Velocity-time-integral (VTI)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Velocity-time-integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: cm.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Tricuspid annular plane systolic excursion (TAPSE)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Tricuspid annular plane systolic excursion (TAPSE) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: mm.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Cardiac output (CO)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Cardiac output (CO) calculated from velocity-time integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: L/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Stroke volume (SV)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Stroke volume (SV) calculated from velocity-time-integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: mL.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Diaphragm displacement
大体时间:At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
Diaphragm displacement measured by bedside diaphragm ultrasound, assessed in two out of the three APRV experimental conditions only when spontaneous breathing was present.
Unit: mm.
|
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
|
Diaphragm thickening fraction
大体时间:At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
Diaphragm thickening fraction measured by bedside diaphragm ultrasound, assessed in two out of the three APRV experimental conditions only when spontaneous breathing was present.
Unit: %.
|
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
|
Lung 12-zone ultrasound score
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Lung ultrasound score based on 12-zone lung ultrasound assessment, assessed at baseline and under three APRV experimental conditions.
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Overdistension (OD) pixel count
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Pixel count of lung overdistension (OD), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: pixels.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Overdistension (OD) proportion
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Proportion of lung overdistension (OD) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Recruitment (CR) pixel count
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Pixel count of lung recruitment (CR), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: pixels.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Recruitment (CR) proportion
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Proportion of lung recruitment (CR) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Atelectasis (AT) pixel count
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Pixel count of lung atelectasis (AT), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: pixels.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Atelectasis (AT) proportion
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Proportion of lung atelectasis (AT) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence and severity of adverse events
大体时间:During each APRV experimental intervention period
|
Incidence and severity of adverse events during study interventions, focusing on respiratory events, circulatory events and procedure-related adverse events.
Unit: unitless.
|
During each APRV experimental intervention period
|
|
Rate of premature intervention discontinuation for safety concerns
大体时间:During each APRV experimental intervention period
|
Rate of premature discontinuation of study interventions due to safety-related reasons.
Unit: %.
|
During each APRV experimental intervention period
|
|
Inspired oxygen fraction (FiO₂)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Set inspired oxygen fraction, obtained directly from ventilator readings, recorded at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial pH
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial blood pH measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial partial pressure of oxygen (PaO₂)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial partial pressure of oxygen measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial partial pressure of carbon dioxide (PaCO₂)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial partial pressure of carbon dioxide measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial oxygen saturation (SaO₂)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial oxygen saturation measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Bicarbonate (HCO₃-)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Serum bicarbonate (HCO₃-) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmol/L.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Base excess (BE)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Base excess (BE) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmol/L.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial lactate (Lac)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial lactate (Lac) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmol/L.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
PaO₂/FiO₂ ratio
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
PaO₂/FiO₂ ratio calculated from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Alveolar-arterial oxygen difference (A-aDO₂)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Alveolar-arterial oxygen difference calculated from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Correlation analysis among multiple respiratory-hemodynamic-diaphragm parameters
大体时间:Corresponding study time points
|
Explore the correlations among EIT parameters, respiratory mechanics, blood gas analysis, hemodynamics and diaphragm function across three study conditions.
|
Corresponding study time points
|
|
Ventilatory ratio (VR)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Ventilatory ratio (VR), a calculated index reflecting pulmonary dead-space and lung injury severity, is computed from minute ventilation and arterial CO₂ values assessed at baseline and under three APRV experimental conditions.
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Expired tidal volume (VTe)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Expired tidal volume assessed at baseline and under three APRV experimental conditions.
Unit: mL.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Total respiratory rate
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Total respiratory rate assessed at baseline and under three APRV experimental conditions.
Unit: breaths/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Total minute ventilation
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Total minute ventilation assessed at baseline and under three APRV experimental conditions.
Unit: L/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Spontaneous minute ventilation
大体时间:At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
Spontaneous component of minute ventilation assessed under two APRV experimental conditions only when spontaneous breathing was present, derived directly from ventilator readings.
Unit: L/min.
|
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
|
Proportion of spontaneous minute ventilation
大体时间:At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
Proportion of spontaneous minute ventilation relative to total minute ventilation, calculated under two APRV experimental conditions only when spontaneous breathing was present.
Unit: %.
|
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
|
Mechanical power (MP)
大体时间:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Mechanical power of ventilation as an indicator of ventilator-induced lung injury (VILI) risk, obtained directly from ventilator readings at baseline and under three APRV experimental conditions.
Unit: J/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
合作者和调查者
调查人员
- 首席研究员:xiaojing zou, MD、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.